ArticleJournal of gynecologic oncology2026
Update of incidence and survival in patients with cervical cancer in the United States from 2000 to 2021.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe implementation of human papillomavirus-based screening in the early 2000s and advancements in targeted therapies and immunotherapy have necessitated updated insights into the incidence and survival trends of cervical cancer in the U.S.
methodsThis retrospective cohort study used Surveillance, Epidemiology, and End Results (SEER) 17 data on patients diagnosed with primary invasive cervical cancer from 2000 to 2021. Age-adjusted incidence rates were calculated in SEER*Stat software. Trends of incidence were analyzed using Joinpoint regression models to calculate annual percent changes and identify the best-fitting joinpoints. Cox proportional hazards regression was used to evaluate risk factors associated with overall survival (OS).
resultsFrom 2000 to 2021, the incidence of International Federation of Gynecology and Obstetrics (FIGO) IA/IB declined annually by 1.9% and 0.7%, respectively, while the incidence of FIGO IV increased by 0.9% per year. Unadjusted OS declined slightly over the study period (hazard ratio [HR]=1.010; p<0.001), with 5-year OS decreasing from 70.3% in 2000 to 66.4% in 2016. However, after adjusting for age and stage, OS improved significantly (adjusted HR=0.996; p=0.002). Survival gains were primarily observed in patients with FIGO II-IV, whereas outcomes for FIGO I patients remained unchanged. Non-Hispanic Black patients continued to experience disparities in treatment access, including lower rates of postoperative radiotherapy and brachytherapy use.
conclusionThe decline in OS from 2000 to 2021 were associated with a shift toward more advanced-stage diagnoses and older age at diagnosis. Poorer outcomes among non-Hispanic Black patients were partly due to unequal access to optimal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.